Wednesday, July 8, 2026

pharma · Epilepsy · Attention-Deficit/Hyperactivity Disorder (ADHD) · SUPN

SUPERNUS PHARMACEUTICALS

SUPERNUS PHARMACEUTICALS clinical programs — 16 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

9715 Key West Ave, Rockville, Maryland 20850, US HQ
2005 Founded
828 Employees
Public company Type
SUPN · NYSE Ticker
Company details
Status
Public
HQ
9715 Key West Ave, Rockville, Maryland 20850, US
Founded
2005
Employees
828
Programs
55
Drugs
25
Patents
68
Intelligence · Clinical Programs

SUPERNUS PHARMACEUTICALS projects

16 ClinicalTrials.gov programs sponsored by SUPERNUS PHARMACEUTICALS.

SUPERNUS PHARMACEUTICALS has 16 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Brexanolone

    SUPERNUS PHARMACEUTICALS, INC.

    Post Partum Depression

    phase 3 small molecule completed

    1 trial
  2. MYOBLOC

    SUPERNUS PHARMACEUTICALS, INC.

    Sialorrhea

    phase 3 small molecule completed

    2 trials
  3. MYOBLOC Low Dose

    SUPERNUS PHARMACEUTICALS, INC.

    Sialorrhea

    phase 3 small molecule terminated

    1 trial
  4. Oxcarbazepine XR

    SUPERNUS PHARMACEUTICALS, INC.

    Partial Epilepsy

    phase 3 small molecule completed

    1 trial
  5. Phase 2; Low Dose MYOBLOC

    SUPERNUS PHARMACEUTICALS, INC.

    Spasticity

    phase 3 small molecule active

    1 trial
  6. Phase 2; Low Dose MYOBLOC (15,000 Units)

    SUPERNUS PHARMACEUTICALS, INC.

    Spasticity

    phase 3 small molecule terminated

    1 trial
  7. Placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsies, Partial

    phase 3 small molecule completed

    1 trial
  8. Placebo

    SUPERNUS PHARMACEUTICALS, INC.

    ADHD

    phase 3 small molecule completed

    5 trials
  9. Placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Attention-Deficit/Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    2 trials
  10. Placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Postpartum Depression

    phase 3 small molecule completed

    2 trials
  11. SAGE-547

    SUPERNUS PHARMACEUTICALS, INC.

    Super-refractory Status Epilepticus

    phase 3 small molecule completed

    2 trials
  12. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Huntington's Disease

    phase 3 small molecule terminated

    2 trials
  13. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule terminated

    2 trials
  14. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder

    phase 3 small molecule terminated

    1 trial
  15. SPN-810 (18 mg)

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    2 trials
  16. apomorphine infusion

    SUPERNUS PHARMACEUTICALS, INC.

    Idiopathic Parkinson's Disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does SUPERNUS PHARMACEUTICALS have?

16 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.